Literature DB >> 16918475

Structure and mechanism of arylamine N-acetyltransferases.

I M Westwood1, A Kawamura, E Fullam, A J Russell, S G Davies, E Sim.   

Abstract

Arylamine N-acetyltransferases (NATs) are a family of phase II drug-metabolising enzymes which are important in the biotransformation of various aromatic and heterocyclic amines and hydroxylamines, arylhydrazines and arylhydrazides. NATs are present in a wide range of eukaryotes and prokaryotes. Humans have two functional NAT isoforms, both of which are highly polymorphic. The pharmacogenetics of NATs is an area which has been extensively studied. The determination of the X-ray crystal structure of NAT from Salmonella typhimurium led to the identification of the catalytically essential triad of residues: Cys-His-Asp, which is present in all functional NAT enzymes. Recent co-crystallisation data and in silico docking studies of NAT from Mycobacterium smegmatis with substrates and inhibitors have aided the identification of important contact residues within the active site. The X-ray crystal structures of four prokaryotic NAT proteins have now been determined, and these have been used to generate structural models of eukaryotic NATs, providing valuable insight into their active-site architecture. In addition to aiding crystallographic experiments, recent progress in the production of recombinant prokaryotic and eukaryotic NATs has allowed comparative studies of the kinetics and activity profiles of these enzymes. In this review we present an overview of recent structural and activity studies on NAT enzymes, and we outline how in silico methods may be used to predict NAT protein-ligand interactions based on the current knowledge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918475     DOI: 10.2174/156802606778108979

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  19 in total

1.  Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors:  Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Kinetic and chemical mechanism of arylamine N-acetyltransferase from Mycobacterium tuberculosis.

Authors:  Alison L Sikora; Brenda A Frankel; John S Blanchard
Journal:  Biochemistry       Date:  2008-09-17       Impact factor: 3.162

Review 3.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

4.  Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site.

Authors:  Areej M Abuhammad; Edward D Lowe; Elizabeth Fullam; Martin Noble; Elspeth F Garman; Edith Sim
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

5.  Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene.

Authors:  Larissa Wakefield; Hilary Long; Nathan Lack; Edith Sim
Journal:  Mamm Genome       Date:  2007-05-09       Impact factor: 2.957

Review 6.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 7.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

8.  Crystallization and preliminary crystallographic analysis of N-acetyltransferase Mpr1 from Saccharomyces cerevisiae.

Authors:  Takao Hibi; Hiromi Yamamoto; Genichi Nakamura; Hiroshi Takagi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-01-31

9.  Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars.

Authors:  Isaac M Westwood; Sanjib Bhakta; Angela J Russell; Elizabeth Fullam; Matthew C Anderton; Akane Kawamura; Andrew W Mulvaney; Richard J Vickers; Veemal Bhowruth; Gurdyal S Besra; Ajit Lalvani; Stephen G Davies; Edith Sim
Journal:  Protein Cell       Date:  2010-03-18       Impact factor: 14.870

Review 10.  Arylamine N-acetyltransferases in mycobacteria.

Authors:  Edith Sim; James Sandy; Dimitrios Evangelopoulos; Elizabeth Fullam; Sanjib Bhakta; Isaac Westwood; Anna Krylova; Nathan Lack; Martin Noble
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.